Drugs / ULSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07086521 | Dec 2025 → Sep 2028 expected | facioscapulohumeral muscular dystrophy | Restem, LLC. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ULSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07086521 ↗ |
| Modality | Cell therapy | “umbilical cord lining-derived stem cell product (ULSC)” NCT07086521 ↗ |
| Route | Intravenous | “ULSC administered in two intravenous (IV) doses of 100 million cells per dose.” NCT07086521 ↗ |